Ribociclib Delays Quality of Life Deterioration
Adding Ribociclib to Fulvestrant maintains QoL and delays deterioration in key functional domains compared to placebo.
Global Health HR
0.81
Favors Ribociclib (NS)
Pain Severity HR
0.77
23% Risk Reduction
Median TTD Gain
+2.8 mo
Time to 10% Deterioration
Study Design: MONALEESA-3
- Design: Phase III, Randomized, Double-blind, Placebo-controlled
- Arms: Ribociclib + Fulvestrant (N=484) vs. Placebo + Fulvestrant (N=242)
- Population: Postmenopausal HR+/HER2- Advanced Breast Cancer
- Primary Endpoint: PFS (reported separately); Secondary: PROs (EORTC QLQ-C30, BPI-SF)
Risk Paradox: Hazard Ratios for Deterioration
Hazard Ratios < 1.0 indicate Ribociclib delays deterioration. Despite adding a drug, patients stayed stable longer.
Delaying Deterioration: Median Time to 10% Decline
Ribociclib extended the time before patients felt a significant decline in Global Health Status by 2.8 months.
Baseline Comparability
Baseline Global Health Status scores were comparable between arms, ensuring validity of the longitudinal comparison.
Pain Severity: Risk Reduction
Patients on Ribociclib had a 23% lower risk of definitive deterioration in pain severity compared to placebo.
Editorial Conclusion
"In addition to significantly prolonging PFS and OS compared with placebo plus fulvestrant, adding ribociclib to fulvestrant maintains HRQOL. The delay in deterioration of global health status and pain scores suggests a net clinical benefit where efficacy does not come at the cost of patient well-being."
Data Appendix
| Metric | Group | Value | Source |
|---|
Source: Fasching et al. The Breast 54 (2020) 148-154. DOI: 10.1016/j.breast.2020.09.008